RU2009133096A - METHOD FOR DIFFERENTIATED TREATMENT OF DIFFUSIVE B-CELLULAR LYMPHOSARCOM OF Lymphoid Adults - Google Patents
METHOD FOR DIFFERENTIATED TREATMENT OF DIFFUSIVE B-CELLULAR LYMPHOSARCOM OF Lymphoid Adults Download PDFInfo
- Publication number
- RU2009133096A RU2009133096A RU2009133096/15A RU2009133096A RU2009133096A RU 2009133096 A RU2009133096 A RU 2009133096A RU 2009133096/15 A RU2009133096/15 A RU 2009133096/15A RU 2009133096 A RU2009133096 A RU 2009133096A RU 2009133096 A RU2009133096 A RU 2009133096A
- Authority
- RU
- Russia
- Prior art keywords
- days
- day
- block
- dexamethasone
- methotrexate
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Способ дифференцированного лечения диффузных В-крупноклеточных лимфосарком лимфоидных органов взрослых, включающий 5-дневную предфазу циклофосфаном и дексаметазоном и последовательную блоковую интенсивную химиотерапию препаратами, вводимыми внутривенно: метотрексат, винкристин, доксорубицин, ифосфамид, вепезид, цитозар и перорально дексаметазон, отличающийся тем, что после предфазовой химиотерапии проводят последовательно 6-кратную блоковую интенсивную химиотерапию А-В-А-В-С-А или А-В-А-В-А-В, при этом блок А проводят путем введения внутривенно препаратов: метотрексат 1500 мг/м2 и винкристин 2 мг в 1-ый день, доксорубицин 25 мг/м2 в 1 и 2 дни, вепезид 100 мг/м2 и цитозар 150 мг/м2 - только в 4 и 5 дни и ифосфамид внутривенно 800 мг/м2, дексаметазон 20 мг в таблетках в 1-5 дни, далее проводят блок В путем внутривенного введения препаратов: метотрексат 1500 мг/м2 и винкристин 2 мг в 1-ый день, доксорубицин 25 мг/м2 только в 4 и 5 дни, циклофосфан 200 мг/м2 и дексаметазон 20 мг в таблетках в 1-5 дни, затем еще 2 блока А и В и при наличии полной ремиссия проводят еще 2 блока А-В, а в случае ее отсутствия проводят блок С путем внутривенного введения препаратов: метотрексат 1500 мг/м2 и винбластин 10 мг в 1-ый день, цитозар 2000 мг/м2 2 раза в день во 2 и 3 дни, вепезид 150 мг/м2 в 3, 4 и 5 дни, дексаметазон 20 мг в таблетках в 1-5 дни, и затем при наличии полной ремиссии проводят 1 блок А, при этом курс лечения составляет 4,5-5 месяцев, интервалы между блоками 21 день. A method for the differentiated treatment of diffuse B-large-cell lymphosarcomas of adult lymphoid organs, including a 5-day prephase with cyclophosphamide and dexamethasone and sequential intensive block chemotherapy with intravenous drugs: methotrexate, vincristine, doxorubicin, ifosfamide, vepezide, differently cytosis, cytosis pre-phase chemotherapy is carried out sequentially 6-fold intensive block chemotherapy A-B-A-B-C-A or A-B-A-B-A-B, while block A is carried out by introducing into Nutrient preparations: methotrexate 1500 mg / m2 and vincristine 2 mg on day 1, doxorubicin 25 mg / m2 on days 1 and 2, vepezid 100 mg / m2 and cytosar 150 mg / m2 - only on days 4 and 5 and ifosfamide intravenously 800 mg / m2, dexamethasone 20 mg in tablets for 1-5 days, then block B is administered by intravenous administration: methotrexate 1500 mg / m2 and vincristine 2 mg on the 1st day, doxorubicin 25 mg / m2 only in 4 and 5 days, cyclophosphamide 200 mg / m2 and dexamethasone 20 mg in tablets in 1-5 days, then 2 more blocks A and B and, if there is complete remission, 2 more blocks A-B are carried out, and in case of its absence block C is carried out by intravenous administration: methotrexate 1500 mg / m2 and vinblastine 10 mg on the 1st day, cytosar 2000 mg / m2 2 times a day on days 2 and 3, vepezid 150 mg / m2 on days 3, 4 and 5, dexamethasone 20 mg in tablets in 1-5 days, and then in the presence of complete remission spend 1 block A, while the course of treatment is 4.5-5 months, the intervals between blocks are 21 days.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2009133096/15A RU2421217C2 (en) | 2009-09-03 | 2009-09-03 | Method of differentiated treatment of diffuse large b-cell lymphosarcomas of lymphoid organs in adults |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2009133096/15A RU2421217C2 (en) | 2009-09-03 | 2009-09-03 | Method of differentiated treatment of diffuse large b-cell lymphosarcomas of lymphoid organs in adults |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2009133096A true RU2009133096A (en) | 2011-03-10 |
RU2421217C2 RU2421217C2 (en) | 2011-06-20 |
Family
ID=44738240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009133096/15A RU2421217C2 (en) | 2009-09-03 | 2009-09-03 | Method of differentiated treatment of diffuse large b-cell lymphosarcomas of lymphoid organs in adults |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2421217C2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI746449B (en) * | 2015-07-20 | 2021-11-21 | 美商Ai治療公司 | Methods for treating cancer using apilimod |
-
2009
- 2009-09-03 RU RU2009133096/15A patent/RU2421217C2/en active
Also Published As
Publication number | Publication date |
---|---|
RU2421217C2 (en) | 2011-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2964764T3 (en) | Therapeutic combination comprising a cdk inhibitor and oxaliplatin | |
EP1711188B1 (en) | Anti-cancer therapies | |
BR112019007844A2 (en) | treatment of gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoroacyl (and leucovorin) | |
RU2020123665A (en) | PREFERRED DOSAGE REGIMENS G1T38 | |
WO2022111714A1 (en) | Combination therapy for treating pik3ca-mutated cancer | |
JP2015098481A (en) | Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for treatment of neoplasms | |
JP2010525042A5 (en) | ||
RU2009133096A (en) | METHOD FOR DIFFERENTIATED TREATMENT OF DIFFUSIVE B-CELLULAR LYMPHOSARCOM OF Lymphoid Adults | |
JP2019517507A5 (en) | ||
MX2021014523A (en) | Methods of treating cholangiocarcinoma. | |
Shimura et al. | The impact of cross-resistance between paclitaxel and docetaxel for metastatic gastric cancer | |
Holland et al. | Rifampicin for Staphylococcus aureus bacteraemia: give it ARREST | |
Burbridge et al. | Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity. | |
Droz et al. | High-dose chemotherapy in germ-cell tumors | |
CN101965191A (en) | Improved anticancer treatments | |
Saliba et al. | EFFICACY AND SAFETY OF EVEROLIMUS WITH EARLY REDUCTION OR ELIMINATION OF TACROLIMUS IN 719DE NOVOLIVER TRANSPLANT RECIPIENTS: 12 MONTH RESULTS OF A PHASE III, RANDOMIZED, CONTROLLED STUDY: LB-7 | |
Shimada et al. | Outpatient therapy with irinotecan and low-dose cisplatin for metastatic colorectal cancer resistant to 5-fluorouracil | |
Tsavaris et al. | Leucovorin+ 5-fluorouracil plus dipyridamole in leucovorin+ 5-fluorouracil-pretreated patients with advanced colorectal cancer: a pilot study of three different dipyridamole regimens | |
Katsumoto | Cetuximab/irinotecan | |
RU2011105636A (en) | METHOD FOR COMBINED TREATMENT OF NON-SMALL CELL LUNG CANCER II AND III STAGE WITH PRE- AND POSTOPERATIVE CHEMOTHERAPY | |
Gao | Various toxicities: case report | |
Zheng | Melphalan/prednisone/thalidomide | |
Hosojima | Docetaxel/irinotecan/lentinan/tegafur/uracil | |
Sumi | Pazopanib/doxorubicin | |
Enomoto | Acute exacerbation of interstitial lung disease characterised as pneumonitis: 5 case reports |